4SCAR-T / SZGIMI - LARVOL DELTA

Intervention of Bladder Cancer by CAR-T (clinicaltrials.gov) - P1/2 | N=20 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Unknown status ➔ Recruiting | Trial completion date: Dec 2020 ➔ Dec 2029 | Trial primary completion date: Dec 2019 ➔ Dec 2028

Enrollment open • Trial completion date • Trial primary completion date • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma. (PubMed, Mol Cancer) - P1 | "Both single and combined infusions of GD2-specific 4SCAR-T cells in targeting GBM were safe and well tolerated, with no severe adverse events. In addition, GD2-specific 4SCAR-T cells partially mediate antigen loss and activate immune responses in the tumor microenvironment. Validation of our findings in a larger prospective trial is warranted."

CAR T-Cell Therapy • Journal • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

CAR-T Cells Targeting Autoimmune Diseases (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute

CAR T-Cell Therapy • New P1/2 trial • Immunology